Completed OBSERVATIONAL NCT00004306

Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)

Pathogenic Mechanism of Spinocerebellar Ataxia Type 10 (SCA10)

Sponsor: Office of Rare Diseases (ORD)

Updated 10 times since 2017 Last updated: Mar 5, 2012 Started: Nov 30, 1999 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Hereditary Ataxia, this trial is completed. The trial is conducted by Office of Rare Diseases (ORD) and has accumulated 10 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Nov 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Office of Rare Diseases (ORD)
The University of Texas Medical Branch, Galveston

Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Galveston, United States